GlassScriptPhysician profile
Robert L Lynch
NPI 1184644031
$6,106.67
in general payments reported to CMS, 2019-2025
33 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $373 · 2021: $769 · 2022: $541 · 2023: $811 · 2024: $1,209 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,025.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.74 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $480.27 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $400.16 | 2019-2025 | |
| Novo Nordisk INC | $356.42 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $231.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $210.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $204.11 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $182.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $143.51 | 2019-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $128.28 | 2022 | |
| Sunovion Pharmaceuticals INC. | $75.91 | 2021-2022 | |
| Amarin Pharma, INC. | $64.36 | 2019-2020 | |
| Amgen INC. | $62.35 | 2023-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $57.80 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $53.49 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $51.53 | 2023-2025 | Gemtesa |
| Abbvie INC. | $46.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.66 | 2023-2025 | Xifaxan |
| Mylan Specialty L.P. | $43.18 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.08 | 2022-2023 | Trintellix |
| Dexcom, INC. | $34.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $32.94 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $32.74 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $29.41 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $20.10 | 2019 | |
| Mannkind Corporation | $17.51 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.20 | 2025 | Nuzyra |
| Therapeuticsmd, INC. | $15.16 | 2019 | |
| Exact Sciences Corporation | $14.67 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $12.75 | 2019 | |
| Eisai INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.